Fri, Aug 22, 2014, 10:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • bfg007_99 bfg007_99 Aug 4, 1999 4:22 PM Flag

    Don't trade alone

    "The stock surfer at "webmag.com

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • My compliments as well to oldeyegy!
      I'm out at
      107....good timing for once.


      Except for the
      Merrill price target. Which
      I'm not betting we'll see
      short term. My guess.


      xmyope

    • Good call, Oldest one!

      As you know, pigs go to market and hogs get slaughtered!!

      Best, the Deuce

    • XMyope is correct. My pc was totally corrupted!
      Thanks to Dell (at no charge to me) the problem was
      eventually corrected. Shortly after that, however, my phone
      line was corrupted.....could that be from reading this
      board? Who knows!!

      Best, the Deuce

    • I am estatic AGN is out of that business. Not a "fit" as the cost of sales had to be high.

    • Restored price target to $120 share. Restored Restasis into revenue model.

      MktCap

    • The M.D. Formulations, domestic & international, and M.D.Fort� international, brands were sold to a group of investors who call themselves M.D.F. Acquisitions Corp. located in San Diego, CA.

    • Very good move. Your actions indicate the
      knowledge you have w/ AGN, the FDA and the Industry. Alot
      of us would be very happy if "all" eyecare companies
      would trade at these crazy levels.

      MktCap

    • too rich 4 me...sold this am at 107 and
      change...its all gone now except a few hundred...the
      announcement said really nothing more than what the panel
      recommended...but this has always been a great kneejerk
      stock...play it up and play it down,but at 45 times 1999 eps
      "i aint gonna be the hog".

    • Dear Eye Care Professional,

      Alcon Takes
      Action on NSAID Distribution and Labeling

      Alcon
      Laboratories is greatly concerned with the occurrence of
      serious corneal adverse events reported in the U.S.
      associated with the aggressive use of topical non-steroidal
      anti-inflammatory drugs (NSAIDs) before, during, and after cataract
      surgery. We have been diligently investigating all reports
      in an attempt to determine factors that may be
      contributing to the occurrence of such adverse events. These
      investigations have included visits to doctors� offices,
      telephone interviews with doctors, and exchanges of
      information with ASCRS. We have also been working closely
      with the Food and Drug Administration to keep them
      advised of our investigations and to obtain the benefit
      of their broader perspective, including MedWatch.


      To date, our investigations of adverse events
      associated with our Diclofenac Sodium Ophthalmic Solution
      (DSOS) suggest that the increase in these events
      correlates both with a general increase in topical NSAID use
      and also an increased utilization of DSOS in
      association with ocular surgery. These adverse events appear
      to be more prevalent in patients with corneal
      problems, including those with dry eye or corneal
      epithelial defects.

      The potential for topical NSAIDs
      to slow or delay healing, and cause keratitis and
      corneal erosions is well established for this class of
      compounds. What is not well established are the patterns of
      pre-, peri-, and extended post-surgical NSAID use and
      their relationship to the occurrence and severity of
      corneal adverse events. Additionally, the association of
      these adverse events with particular subsets of
      patients and the extensive concomitant use with other
      medications, particularly topical steroids, are less well
      understood.

      * * * * *

      We are confident that
      our products, when used according to label
      directions, are safe and effective. However, because we are
      concerned about these issues, Alcon has decided, in the
      interest of patient safety, to suspend distribution of our
      NSAID products, Diclofenac Sodium Ophthalmic Solution
      and Profenal (suprofen) Sterile Ophthalmic Solution
      1%.

      Alcon has initiated discussions with the Food and Drug
      Administration on the need to develop new labeling that more
      specifically addresses the potential for problems associated
      with topical NSAID use. It is expected that labeling
      changes will be designed to include improved directions
      for use and additional warnings and precautions
      concerning the potential for serious corneal adverse events,
      particularly in susceptible populations.

    • FDA prepares report
      While ASCRS begins its
      own study, the FDA has been following these adverse
      events and is preparing a report for its own regulatory
      officials.

      Some physicians report adverse events
      directly to the agency, although only the drug makers are
      obligated to do so.

      According to Wiley Chambers,
      MD, the agency�s deputy director for
      anti-inflammatory, analgesic and ophthalmic drug products,
      epidemiologists monitor the adverse event reporting program,
      called Med Watch. Those agents have prepared a
      consultative report.

      Although Dr. Chambers could not
      cite specific elements of the report, he did say that
      there have not been an undue number of cases reported
      to the agency to date, and no clear pattern has
      formed.

      Dr. Chambers said reports to Med Watch
      about corneal melting have not always identified
      specifically which NSAID was prescribed or dispensed. Adverse
      events are not always clearly defined, and the term
      �corneal melt� might be applied to any kind of keratitis,
      whether it perforates or not.

      �NSAIDs, along with
      steroids, are known to delay wound healing,� Dr. Chambers
      said. �Some of the events that have been reported are
      not unlike what has been reported in the past with
      steroids and are consistent with current labeling.�


      Current labeling for NSAIDs and steroidals alike notes a
      greater likelihood of keratitis and other corneal
      problems postoperatively. The definition of a corneal
      problem is one issue under discussion.

      �These are
      post-surgical cases,� he said. �You have wounds there that need
      to heal to have strong and secure tissue. If that
      does not heal, then you are at risk of further
      perforation or other events going on. If you add multiple
      products that cause wounds not to heal, then you are at
      further risk. Steroids are known to do that;
      nonsteroidals are known to do that.�

    • View More Messages
 
AGN
165.56+1.18(+0.72%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Salesforce.com, Inc
NYSEFri, Aug 22, 2014 4:00 PM EDT